McKesson Pharmaceuticals contract for $630.2M awarded by DOJ's Bureau of Prisons for FY26

Contract Overview

Contract Amount: $630,200 ($630.2K)

Contractor: Mckesson Corporation

Awarding Agency: Department of Justice

Start Date: 2025-10-23

End Date: 2026-08-07

Contract Duration: 288 days

Daily Burn Rate: $2.2K/day

Competition Type: FULL AND OPEN COMPETITION

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: FY26 B1 MCKESSON PHARMACUTICALS

Place of Performance

Location: IRVING, DALLAS County, TEXAS, 75039

State: Texas Government Spending

Plain-Language Summary

Department of Justice obligated $630,200 to MCKESSON CORPORATION for work described as: FY26 B1 MCKESSON PHARMACUTICALS Key points: 1. Contract awarded to a single, large pharmaceutical distributor, indicating a focus on established supply chains. 2. The firm-fixed-price structure aims to control costs for pharmaceutical preparations. 3. Delivery order type suggests a need for specific, scheduled pharmaceutical supplies. 4. The contract duration of 288 days points to a defined period of need for these pharmaceuticals. 5. Awarded by the Federal Prison System, highlighting the critical role of pharmaceuticals in correctional healthcare. 6. The North American Industry Classification System (NAICS) code 325412 indicates a focus on pharmaceutical preparation manufacturing.

Value Assessment

Rating: good

This contract's value of $630.2 million for pharmaceutical preparations appears substantial, reflecting the scale of the Federal Prison System's needs. Benchmarking against similar large-scale pharmaceutical contracts for correctional facilities or federal healthcare providers would be necessary for a precise value-for-money assessment. The firm-fixed-price (FFP) contract type is generally favorable for the government in managing cost certainty, especially for standardized goods like pharmaceuticals, assuming the pricing reflects competitive market rates.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, suggesting that multiple qualified bidders had the opportunity to submit proposals. This approach is designed to foster a competitive environment, potentially leading to better pricing and terms for the government. The specific number of bidders is not provided, but the 'full and open' designation implies a robust competition process was intended.

Taxpayer Impact: Full and open competition generally benefits taxpayers by encouraging a wider range of suppliers to bid, which can drive down prices and improve the quality of goods and services received.

Public Impact

Inmates within the Federal Prison System will benefit from access to necessary pharmaceutical preparations. The contract ensures the supply of essential medications for healthcare services provided by the Bureau of Prisons. The geographic impact is nationwide, covering all federal correctional facilities requiring these pharmaceuticals. This contract supports the pharmaceutical manufacturing and distribution workforce involved in fulfilling the order.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Potential for price fluctuations in the pharmaceutical market not fully captured by a single fixed-price contract if market conditions change significantly.
Dependence on a single large awardee for a critical supply chain element could pose a risk if the contractor faces disruptions.

Positive Signals

Firm-fixed-price contract provides cost certainty for the government.
Awarded under full and open competition, suggesting a competitive process aimed at achieving best value.
The contract specifies a clear delivery period, aligning with the government's defined needs.

Sector Analysis

The pharmaceutical preparation manufacturing sector is a critical component of the broader healthcare industry, characterized by high regulatory standards and significant research and development investment. This contract falls within the government's procurement of essential medical supplies for its inmate population. Comparable spending benchmarks would involve analyzing other federal agencies' or large state correctional systems' pharmaceutical procurement contracts, which often run into hundreds of millions of dollars annually due to the scale of demand.

Small Business Impact

The data indicates this contract was not set aside for small businesses (ss: false, sb: false). McKesson Corporation is a large, established entity. While this specific award may not directly benefit small businesses through set-asides, large prime contractors are often required to meet subcontracting goals with small businesses on their overall contracts. The impact on the small business ecosystem would depend on McKesson's subcontracting plans for this particular delivery order.

Oversight & Accountability

Oversight for this contract would primarily fall under the Department of Justice's Bureau of Prisons contracting officers and program managers. Accountability measures are embedded in the firm-fixed-price contract terms, requiring delivery of specified pharmaceutical preparations by the deadline. Transparency is generally maintained through federal procurement databases like FPDS, where contract awards are reported. The Inspector General for the Department of Justice may conduct audits or investigations into contract performance and compliance.

Related Government Programs

Federal Prison System Medical Services
Department of Veterans Affairs Pharmaceutical Contracts
TRICARE Pharmacy Program
General Services Administration (GSA) Schedules for Pharmaceuticals

Risk Flags

Potential for drug shortages impacting supply chain reliability.
Price volatility in the pharmaceutical market.
Contractor performance risks related to delivery timelines.
Ensuring compliance with all regulatory requirements for pharmaceutical handling and distribution.

Frequently Asked Questions

What is this federal contract paying for?

Department of Justice awarded $630,200 to MCKESSON CORPORATION. FY26 B1 MCKESSON PHARMACUTICALS

Who is the contractor on this award?

The obligated recipient is MCKESSON CORPORATION.

Which agency awarded this contract?

Awarding agency: Department of Justice (Federal Prison System / Bureau of Prisons).

What is the total obligated amount?

The obligated amount is $630,200.

What is the period of performance?

Start: 2025-10-23. End: 2026-08-07.

What is McKesson Corporation's track record with federal pharmaceutical contracts, particularly with the Bureau of Prisons?

McKesson Corporation is a major pharmaceutical distributor and healthcare company with a long history of contracting with various U.S. federal agencies, including the Department of Defense, Department of Veterans Affairs, and the Bureau of Prisons. They are frequently awarded large contracts for the supply of pharmaceuticals and medical supplies due to their extensive distribution network and product catalog. Historical data from federal procurement databases would show numerous awards to McKesson across different agencies and programs. Their track record generally reflects their position as a leading supplier, though like any large contractor, specific contract performance can vary. For the Bureau of Prisons, McKesson has been a consistent provider of pharmaceuticals, fulfilling needs across numerous correctional facilities.

How does the $630.2 million value of this contract compare to historical spending on pharmaceuticals by the Federal Prison System?

The $630.2 million figure represents a significant investment in pharmaceutical preparations for FY26. To contextualize this, one would need to examine historical spending patterns of the Bureau of Prisons (BOP) on pharmaceuticals over the past several fiscal years. Typically, the BOP's annual pharmaceutical spending can range from several hundred million to over a billion dollars, depending on the specific needs, contract vehicles utilized, and the inmate population size. A $630.2 million award for a single fiscal year suggests it is a substantial portion of their pharmaceutical budget, possibly covering a broad range of medications or a significant portion of their annual requirement through this specific contract vehicle. Comparing this to prior years' total pharmaceutical expenditures would reveal if this represents an increase, decrease, or stable level of spending.

What are the primary risks associated with this firm-fixed-price contract for pharmaceutical preparations?

The primary risks for the government in a firm-fixed-price (FFP) contract for pharmaceuticals, despite its cost certainty benefits, revolve around potential overpricing if the fixed price was set too high due to insufficient competition or market intelligence at the time of award. Another risk is the contractor's ability to maintain supply chain integrity and timely delivery, especially given the critical nature of medications. If McKesson faces unforeseen supply chain disruptions (e.g., manufacturing issues, transportation delays, drug shortages), it could impact the availability of essential medicines for inmates. While FFP shifts most cost overrun risk to the contractor, the government bears the risk of receiving potentially less value if market prices decrease significantly post-award or if the initial price was not optimally negotiated.

What does the 'Delivery Order' (AW: DELIVERY ORDER) designation imply for the execution and management of this contract?

The 'Delivery Order' designation means this contract is likely a type of indefinite-delivery/indefinite-quantity (IDIQ) contract, or a similar vehicle, where specific quantities and delivery schedules are established through individual orders placed against a larger contract. In this case, the $630.2 million likely represents the total estimated value or ceiling for all delivery orders that can be placed within the contract period. This approach allows the Bureau of Prisons flexibility to order pharmaceuticals as needed throughout the contract duration, rather than committing to a massive upfront purchase. It requires diligent management of each delivery order to ensure timely receipt, proper quantities, and adherence to the specified delivery locations within the federal prison system.

How does the North American Industry Classification System (NAICS) code 325412, 'Pharmaceutical Preparation Manufacturing,' align with the supplier, McKesson Corporation?

The NAICS code 325412, 'Pharmaceutical Preparation Manufacturing,' describes establishments primarily engaged in manufacturing pharmaceutical preparations (e.g., pharmaceutical drugs, biological and microbiological non-diagnostic products). While McKesson Corporation is a major distributor of pharmaceuticals, they also engage in manufacturing and packaging activities, or they may be acting as a prime contractor representing multiple manufacturers under this code. Their extensive operations often encompass various aspects of the pharmaceutical supply chain, including manufacturing, packaging, and distribution. Therefore, this NAICS code is relevant as it covers the core business activity related to the preparation and supply of pharmaceuticals, even if McKesson's role might also include significant distribution functions.

What are the implications of the contract being awarded in Texas (ST: TX, SN: TEXAS) for the Bureau of Prisons' supply chain?

The indication that the contract is associated with Texas (ST: TX, SN: TEXAS) likely refers to the location of the contractor's facility or a significant operational hub relevant to this award, rather than the delivery destination for all pharmaceuticals. McKesson has major distribution centers and operations across the United States. If a key facility for this contract is in Texas, it could streamline logistics for federal prisons located within or near that region. However, given the nationwide scope of the Bureau of Prisons, pharmaceuticals procured under this contract will likely be distributed to facilities across the country. The Texas designation might influence initial warehousing or processing, but the ultimate delivery network will be broader.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 6555 STATE HIGHWAY 161, IRVING, TX, 75039

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $630,200

Exercised Options: $630,200

Current Obligation: $630,200

Actual Outlays: $260,154

Contract Characteristics

Multi-Year Contract: Yes

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: 36W79720D0001

IDV Type: IDC

Timeline